U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07389629) titled 'Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC' on Jan. 29.
Brief Summary: Through the combination of aparolitovorelli monoclonal antibody and lenvatinib neoadjuvant therapy, partial nephrectomy can be successfully and safely performed in patients with localized renal cell carcinoma (T1N0M0 or T2N0M0) who have indications for kidney preservation surgery but have difficulty in preserving the kidney (R.E.N.A.L. score >= 10).
Study Start Date: Nov. 21, 2025
Study Type: INTERVENTIONAL
Condition:
Iparomlimab and Tuvonralimab
Clear Cell Renal Cell Carcinoma
Neoadjuvant Therapy
Interv...